Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Common Equity (2023 - 2026)

Camp4 Therapeutics' Common Equity history spans 3 years, with the latest figure at $47.7 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 24.45% to $47.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $47.7 million, a 24.45% decrease, with the full-year FY2025 number at $47.7 million, down 24.45% from a year prior.
  • Common Equity hit $47.7 million in Q4 2025 for Camp4 Therapeutics, down from $58.7 million in the prior quarter.
  • Over the last five years, Common Equity for CAMP hit a ceiling of $63.1 million in Q4 2024 and a floor of -$159.0 million in Q3 2024.
  • Historically, Common Equity has averaged -$41.6 million across 3 years, with a median of -$35.8 million in 2023.
  • The widest YoY moves for Common Equity: up 151.03% in 2024, down 42.51% in 2024.
  • Tracing CAMP's Common Equity over 3 years: stood at -$123.7 million in 2023, then skyrocketed by 151.03% to $63.1 million in 2024, then decreased by 24.45% to $47.7 million in 2025.
  • Business Quant data shows Common Equity for CAMP at $47.7 million in Q4 2025, $58.7 million in Q3 2025, and $40.0 million in Q2 2025.